FDA advisors recommend approval of novel agent for pulmonary hypertension

The unanimous vote was to okay the drug, called riociguat, for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

Source: theHeart.org - August 8, 2013 Category: Cardiology Source Type: news